Tags

Type your tag names separated by a space and hit enter

Stone forming risk of calcium citrate supplementation in healthy postmenopausal women.

Abstract

PURPOSE

We evaluated the effect of calcium citrate supplementation alone or in combination with potassium citrate on the stone forming propensity in healthy postmenopausal women.

MATERIALS AND METHODS

A total of 18 postmenopausal women without stones underwent a randomized trial of 4 phases comprised of 2 weeks of treatment with placebo, calcium citrate (400 mg calcium twice daily), potassium citrate (20 mEq twice daily), and calcium citrate and potassium citrate (at same doses). During the last 2 days of each phase urine was collected in 24-hour pools for complete stone risk analysis.

RESULTS

Compared to placebo, calcium citrate increased urinary calcium and citrate but decreased urinary oxalate and phosphate. Urinary saturation of calcium oxalate, brushite and undissociated uric acid did not change. Potassium citrate decreased urinary calcium, and increased urinary citrate and pH. It decreased urinary saturation of calcium oxalate and undissociated uric acid, and did not change the saturation of brushite. When calcium citrate was combined with potassium citrate, urinary calcium remained high, urinary citrate increased even further and urinary oxalate remained reduced from the calcium citrate alone, thereby marginally decreasing the urinary saturation of calcium oxalate. Urinary pH increased, decreasing urinary undissociated uric acid. The increase in pH increased the saturation of brushite despite the decrease in urinary phosphorus.

CONCLUSIONS

Calcium citrate supplementation does not increase the risk of stone formation in healthy postmenopausal women. The co-administered potassium citrate may provide additional protection against formation of uric acid and calcium oxalate stones.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8885, USA. Khashayar.sakhaee@utsouthwestern.edu

    , ,

    Source

    The Journal of urology 172:3 2004 Sep pg 958-61

    MeSH

    Aged
    Calcium
    Calcium Citrate
    Calcium Phosphates
    Citric Acid
    Dietary Supplements
    Drug Therapy, Combination
    Female
    Humans
    Hydrogen-Ion Concentration
    Middle Aged
    Osteoporosis, Postmenopausal
    Oxalates
    Phosphorus
    Postmenopause
    Potassium Citrate
    Risk Factors
    Uric Acid
    Urinary Calculi

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    15311008

    Citation

    Sakhaee, Khashayar, et al. "Stone Forming Risk of Calcium Citrate Supplementation in Healthy Postmenopausal Women." The Journal of Urology, vol. 172, no. 3, 2004, pp. 958-61.
    Sakhaee K, Poindexter JR, Griffith CS, et al. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. J Urol. 2004;172(3):958-61.
    Sakhaee, K., Poindexter, J. R., Griffith, C. S., & Pak, C. Y. (2004). Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. The Journal of Urology, 172(3), pp. 958-61.
    Sakhaee K, et al. Stone Forming Risk of Calcium Citrate Supplementation in Healthy Postmenopausal Women. J Urol. 2004;172(3):958-61. PubMed PMID: 15311008.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. AU - Sakhaee,Khashayar, AU - Poindexter,John R, AU - Griffith,Carolyn S, AU - Pak,Charles Y C, PY - 2004/8/18/pubmed PY - 2004/9/4/medline PY - 2004/8/18/entrez SP - 958 EP - 61 JF - The Journal of urology JO - J. Urol. VL - 172 IS - 3 N2 - PURPOSE: We evaluated the effect of calcium citrate supplementation alone or in combination with potassium citrate on the stone forming propensity in healthy postmenopausal women. MATERIALS AND METHODS: A total of 18 postmenopausal women without stones underwent a randomized trial of 4 phases comprised of 2 weeks of treatment with placebo, calcium citrate (400 mg calcium twice daily), potassium citrate (20 mEq twice daily), and calcium citrate and potassium citrate (at same doses). During the last 2 days of each phase urine was collected in 24-hour pools for complete stone risk analysis. RESULTS: Compared to placebo, calcium citrate increased urinary calcium and citrate but decreased urinary oxalate and phosphate. Urinary saturation of calcium oxalate, brushite and undissociated uric acid did not change. Potassium citrate decreased urinary calcium, and increased urinary citrate and pH. It decreased urinary saturation of calcium oxalate and undissociated uric acid, and did not change the saturation of brushite. When calcium citrate was combined with potassium citrate, urinary calcium remained high, urinary citrate increased even further and urinary oxalate remained reduced from the calcium citrate alone, thereby marginally decreasing the urinary saturation of calcium oxalate. Urinary pH increased, decreasing urinary undissociated uric acid. The increase in pH increased the saturation of brushite despite the decrease in urinary phosphorus. CONCLUSIONS: Calcium citrate supplementation does not increase the risk of stone formation in healthy postmenopausal women. The co-administered potassium citrate may provide additional protection against formation of uric acid and calcium oxalate stones. SN - 0022-5347 UR - https://www.unboundmedicine.com/medline/citation/15311008/Stone_forming_risk_of_calcium_citrate_supplementation_in_healthy_postmenopausal_women_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-5347(05)61532-7 DB - PRIME DP - Unbound Medicine ER -